Abstract
Liposomal formulations represent a significant advancement in the field of oncology, providing innovative solutions for the delivery of chemotherapeutic agents. These nanoscale carriers, made of phospholipid bilayers, enhance drug stability and allow for targeted delivery to tumor tissues, thereby improving the therapeutic index of anticancer medications. By altering the pharmacokinetics and biodistribution of these drugs, liposomes help reduce systemic side effects while increasing the concentration of therapeutic agents at the tumor site. Recent developments in liposomal technology have led to the creation of targeted liposomes, which can bind specifically to cancer cells, enhancing treatment accuracy. This review examines the various applications of liposomes in cancer treatment, discusses important clinical trials, identifies challenges in formulation and delivery, and considers future directions for integrating liposomal therapies into routine oncology practice. As ongoing research progresses, liposomes are poised to play a crucial role in advancing cancer treatment strategies and improving patient outcomes. Additionally, we discuss the challenges associated with their clinical translation and future perspectives in optimizing liposome formulations for personalized cancer therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
